Cytology and Human Papillomavirus Screening Test Results Associated With 2827 Histopathologic Diagnoses of Cervical Intraepithelial Neoplasia 2/3

被引:5
|
作者
Zhao, Chengquan [1 ]
Amin, Milon [1 ]
Weng, Baoying [2 ]
Chen, Xiangbai [2 ]
Kanbour-Shakir, Amal [1 ]
Austin, R. Marshall [1 ]
机构
[1] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
[2] Conemaugh Hlth Syst, Dept Pathol, Johnstown, PA USA
关键词
LIQUID-BASED CYTOLOGY; FOLLOW-UP FINDINGS; 2006 CONSENSUS GUIDELINES; ATYPICAL SQUAMOUS-CELLS; DISEASE RISK-ASSESSMENT; PAPANICOLAOU TEST; CONVENTIONAL CYTOLOGY; UNDETERMINED SIGNIFICANCE; DNA DETECTION; USEFUL OPTION;
D O I
10.5858/arpa.2012-0307-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Cervical screening in the United States increasingly involves newer US Food and Drug Administration-approved cytologic methods and adjunctive high-risk human papillomavirus (hrHPV) DNA testing. Objective.-To document cervical screening test performance preceding histopathologic cervical intraepithelial neoplasia (CIN) 2/3 diagnoses. Design.-Preceding screening test results with computer-imaged, liquid-based cytology (LBC) and hrHPV results were analyzed for 2827 patients with histopathologic CIN 2/3 diagnoses. Results.-Of 2827 patients with CIN 2/3 diagnoses, 2074 (73.4%) had system LBC findings within 4 months of CIN 2/3 diagnoses: high-grade squamous intraepithelial lesion (n = 862; 41.6%), low-grade squamous intraepithelial lesion (n = 464; 22.4%), atypical squamous cells of undetermined significance (n = 445; 21.5%), atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (n 288; 13.9%), and atypical glandular cells/adenocarcinoma in situ (n = 15; 0.7%). Of the 2827 patients, 1488 (52.6%) also had earlier system LBC results at more than 4 months to 3 years before CIN 2/3 diagnoses: one or more abnormal LBC results (n 978; 65.7%), one or more negative LBC results (n = 911; 61.2%), both abnormal and negative LBC (n = 401; 26.9%). Of 807 patients with hrHPV cotest results within 4 months of CIN 2/3 diagnoses, 786 (97.4%) had hrHPV(+) results. Of 454 patients who also had earlier hrHPV results at more than 4 months to 3 years before CIN 2/3 diagnoses: 377 (83.0%) had one or more hrHPV(+) result, 110 (24.2%) had one or more hrHPV(-) result, and 33 (7.3%) had both positive and negative HPV results. Conclusion.-Patients with histopathologic CIN 2/3 had recent abnormal LBC results, most often, high-grade squamous intraepithelial lesions. Among cotested patients, 97.4% (786 of 807) tested hrHPV(+). However, a significant number of patients tested during an extended period of several years had earlier negative Papanicolaou or negative HPV test results, suggesting the recent development of some CIN 2/3 lesions and supporting the value of cotesting for enhanced detection of other developing, small, inaccessible, or nondiagnostic precursor lesions.
引用
收藏
页码:942 / 947
页数:6
相关论文
共 50 条
  • [21] Human papillomavirus deoxyribonucleic acid testing in screening of high grade cervical intraepithelial neoplasia
    Zdenek, H
    Lukac, J
    Jabor, A
    Chvalova, M
    Voracek, J
    Brozkova, H
    SAUDI MEDICAL JOURNAL, 1999, 20 (11) : 861 - 864
  • [22] Human papillomavirus test with cytology triage in organized screening for cervical cancer
    Veijalainen, Olga
    Kares, Saara
    Kujala, Paula
    Tirkkonen, Mika
    Vuento, Risto
    Kholova, Ivana
    Luukkaala, Tiina
    Osuala, Veronika
    Maenpaa, Johanna
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2016, 95 (11) : 1220 - 1227
  • [23] Optimizing the hybrid capture II human papillomavirus test to detect cervical intraepithelial neoplasia
    Howard, M
    Sellors, J
    Kaczorowski, J
    OBSTETRICS AND GYNECOLOGY, 2002, 100 (05): : 972 - 980
  • [24] Risk of cervical intraepithelial neoplasia grade 3 or more diagnoses for human papillomavirus16/18-positive women by cytology and co-infection status
    Ao, Mengyin
    Yao, Xiaoxi
    Zheng, Danxi
    Gu, Xuesai
    Xi, Mingrong
    INFECTIOUS AGENTS AND CANCER, 2023, 18 (01)
  • [25] Risk of cervical intraepithelial neoplasia grade 3 or more diagnoses for human papillomavirus16/18-positive women by cytology and co-infection status
    Mengyin Ao
    Xiaoxi Yao
    Danxi Zheng
    Xuesai Gu
    Mingrong Xi
    Infectious Agents and Cancer, 18
  • [26] Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center
    Domroese, Christian Markus
    Wieland, Ulrike
    Pilch, Henryk
    Einzmann, Thomas
    Schoemig-Markiefka, Birgid
    Mallmann, Peter
    Silling, Steffi
    Mallmann, Michael Rudolf
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2022, 26 (02) : 122 - 126
  • [27] HUMAN PAPILLOMAVIRUS TYPE-16 IN VULVAR CARCINOMA, VULVAR INTRAEPITHELIAL NEOPLASIA, AND ASSOCIATED CERVICAL NEOPLASIA
    HORDING, U
    DAUGAARD, S
    IVERSEN, AKN
    KNUDSEN, J
    BOCK, JE
    NORRILD, B
    GYNECOLOGIC ONCOLOGY, 1991, 42 (01) : 22 - 26
  • [28] HUMAN PAPILLOMAVIRUS L1 CAPSID PROTEIN AND HPV TEST AS A BIOMARKER FOR CERVICAL INTRAEPITHELIAL NEOPLASIA 2+IN WOMEN WITH PERSISTENT ASCUS/LSIL CERVICAL CYTOLOGY
    Yoon, H. J.
    Jeong, M.
    Ki, E. Y.
    Lee, S. J.
    Lee, Y. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A241 - A241
  • [29] bcl-2 immunoreactivity, human papillomavirus DNA, and cervical intraepithelial neoplasia
    Cooper, K
    Haffajee, Z
    Taylor, L
    MODERN PATHOLOGY, 1999, 12 (06) : 612 - 617
  • [30] THE FREQUENCY OF HUMAN PAPILLOMAVIRUS INFECTIONS, WITH OR WITHOUT ASSOCIATED CERVICAL INTRAEPITHELIAL NEOPLASIA, IN CERVICOVAGINAL SMEARS
    ALASIO, L
    PILOTTI, S
    RILKE, F
    ACTA CYTOLOGICA, 1989, 33 (03) : 413 - 414